DRREDDY - Dr. Reddy's Laboratories Ltd. Share Price
Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 1.09 LCr |
| Price/Earnings (Trailing) | 23.18 |
| Price/Sales (Trailing) | 3.12 |
| EV/EBITDA | 11.37 |
| Price/Free Cashflow | 57.39 |
| MarketCap/EBT | 14.13 |
| Enterprise Value | 1.11 LCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 34.79 kCr |
| Rev. Growth (Yr) | 12.4% |
| Earnings (TTM) | 5.74 kCr |
| Earnings Growth (Yr) | 1.3% |
Profitability | |
|---|---|
| Operating Margin | 22% |
| EBT Margin | 22% |
| Return on Equity | 16.93% |
| Return on Assets | 11.62% |
| Free Cashflow Yield | 1.74% |
Price to Sales Ratio
Revenue (Last 12 mths)
Net Income (Last 12 mths)
Growth & Returns | |
|---|---|
| Price Change 1W | 0.00% |
| Price Change 1M | 1.9% |
| Price Change 6M | 11.7% |
| Price Change 1Y | -0.70% |
| 3Y Cumulative Return | 16.3% |
| 5Y Cumulative Return | 5% |
| 7Y Cumulative Return | 14.3% |
| 10Y Cumulative Return | 5.1% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -5.1 kCr |
| Cash Flow from Operations (TTM) | 4.64 kCr |
| Cash Flow from Financing (TTM) | 1.19 kCr |
| Cash & Equivalents | 1.47 kCr |
| Free Cash Flow (TTM) | 1.89 kCr |
| Free Cash Flow/Share (TTM) | 22.67 |
Balance Sheet | |
|---|---|
| Total Assets | 49.43 kCr |
| Total Liabilities | 15.5 kCr |
| Shareholder Equity | 33.93 kCr |
| Current Assets | 25.02 kCr |
| Current Liabilities | 13.03 kCr |
| Net PPE | 7.3 kCr |
| Inventory | 7.11 kCr |
| Goodwill | 1.31 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.08 |
| Debt/Equity | 0.12 |
| Interest Coverage | 24.12 |
| Interest/Cashflow Ops | 16.17 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 8 |
| Dividend Yield | 0.61% |
| Shares Dilution (1Y) | 0.10% |
| Shares Dilution (3Y) | 0.30% |
Latest News and Updates from Dr. Reddy's Lab
Updated May 6, 2025
The Good News
Dr. Reddy’s Laboratories is set to launch Beyfortus, a novel RSV drug for infants, expanding its immunization portfolio.
The drug Beyfortus, containing the monoclonal antibody nirsevimab, has been approved for use in multiple countries globally.
This collaboration with Sanofi marks a significant advancement in protecting children from the RSV disease burden in India.
Updates from Dr. Reddy's Lab
Press Release / Media Release • 22 Sept 2025 Press Release |
Newspaper Publication • 22 Sept 2025 Copies of Newspaper Publications |
General • 18 Sept 2025 Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 |
Press Release / Media Release • 16 Sept 2025 Press Release |
Allotment of ESOP / ESPS • 15 Sept 2025 Allotment of Employee Stock Options |
General • 13 Sept 2025 Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 |
General • 10 Sept 2025 Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 |
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
Summary of Latest Earnings Report from Dr. Reddy's Lab
Summary of Dr. Reddy's Lab's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Last updated:
Last updated:
Revenue Breakdown
Analysis of Dr. Reddy's Lab's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Jun 30, 2025
| Description | Share | Value |
|---|---|---|
| Global Generics | 86.8% | 7.6 kCr |
| Pharmaceutical Services and Active Ingredients | 11.3% | 987.4 Cr |
| Others | 1.9% | 164.3 Cr |
| Total | 8.7 kCr |
Share Holdings
Understand Dr. Reddy's Lab ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
Holding Pattern
Share Holding Details
| Shareholder Name | Holding % |
|---|---|
| G V PRASAD | 11.51% |
| J P Morgan Chase Bank NA | 11.04% |
| SATISH REDDY KALLAM | 10.27% |
| LIFE INSURANCE CORPORATION OF INDIA P & GS FUND | 8.3% |
| KALLAM SATISH REDDY HUF | 3.31% |
| NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2 | 2.25% |
| GUNUPATI VENKATESWARA PRASAD HUF | 1.52% |
| ANURADHA GUNUPATI | 0.01% |
| K SHRAVYA REDDY | 0% |
| K VISHAL REDDY | 0% |
| VSD Holdings & Advisory LLP | 0% |
| APS Trust | 0% |
| SHARATHCHANDRA REDDY GUNUPATI | 0% |
| GUNUPATI MALLIKA REDDY | 0% |
| DEEPTI REDDY KALLAM | 0% |
| G VANI SANJANA REDDY | 0% |
Overall Distribution
Distribution across major stakeholders
Ownership Distribution
Distribution across major institutional holders
Is Dr. Reddy's Lab Better than it's peers?
Detailed comparison of Dr. Reddy's Lab against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 3.94 LCr | 55.67 kCr | +0.10% | -11.90% | 37.97 | 7.08 | - | - |
| DIVISLAB | Divi's Lab | 1.62 LCr | 10.04 kCr | -1.00% | +11.80% | 70.17 | 16.1 | - | - |
| CIPLA | Cipla | 1.25 LCr | 28.77 kCr | -3.20% | +2.60% | 23.09 | 4.33 | - | - |
| LUPIN | Lupin | 91.54 kCr | 23.61 kCr | +1.50% | -6.80% | 24.72 | 3.88 | - | - |
| AUROPHARMA | Aurobindo Pharma | 64.9 kCr | 32.56 kCr | +6.40% | -25.30% | 19.16 | 1.99 | - | - |
Sector Comparison: DRREDDY vs Pharmaceuticals & Biotechnology
Comprehensive comparison against sector averages
Comparative Metrics
DRREDDY metrics compared to Pharmaceuticals
| Category | DRREDDY | Pharmaceuticals |
|---|---|---|
| PE | 23.54 | 36.44 |
| PS | 3.17 | 5.13 |
| Growth | 16.5 % | 9 % |
Performance Comparison
DRREDDY vs Pharmaceuticals (2021 - 2025)
- 1. DRREDDY is among the Top 5 Pharmaceuticals companies by market cap.
- 2. The company holds a market share of 7.8% in Pharmaceuticals.
- 3. In last one year, the company has had an above average growth that other Pharmaceuticals companies.
Income Statement for Dr. Reddy's Lab
Balance Sheet for Dr. Reddy's Lab
Cash Flow for Dr. Reddy's Lab
What does Dr. Reddy's Laboratories Ltd. do?
Dr. Reddy's Laboratories Ltd. is a prominent pharmaceutical company with its stock ticker known as DRREDDY. It boasts a substantial market capitalization of Rs. 100,022.4 Crores and is headquartered in Hyderabad, India.
The company operates globally through various segments:
Global Generics: This segment focuses on manufacturing and marketing both prescription and over-the-counter pharmaceutical products, including branded and generic finished dosages. It also has a presence in the biologics business.
Pharmaceutical Services and Active Ingredients (PSAI): Dr. Reddy's manufactures and markets active pharmaceutical ingredients (APIs) and intermediates that serve as crucial components for finished pharmaceutical products. This segment also provides contract research services and manufactures steroids according to customer specifications.
Others: This sector is dedicated to developing therapies in oncology and inflammation, engaging in R&D for differentiated formulations, and offering digital healthcare and IT-enabled business support services.
The company’s product offerings cover a wide range of therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology.
Founded in 1984, Dr. Reddy's Lab has generated a trailing 12-month revenue of Rs. 32,071.7 Crores, demonstrating significant financial growth with a revenue increase of 50.6% over the past three years. The company is profitable, having achieved a profit of Rs. 5,448.3 Crores in the past four quarters.
Investors are rewarded with dividends, yielding 0.6% annually, with the last distribution being Rs. 8 per share. However, it is notable that the company has diluted its shareholders' stake by 0.3% in the past three years.